The Center for Drug Evaluation and Research at the FDA has issued a draft guidance for information requests and discipline review letters under the generic drug user fee agreement, stating that reviewers will ordinarily communicate their views of possible deficiencies in a generic drug application via a discipline review letter (DRL) as each discipline involved in the review completes its portion of the application.